Press release, Helsinki 9 August 2018 there is a 9.00
Publishing of Nexstim Plc’s interim report for H1 2018
Nexstim Plc (NXTMH:HEX, NXTMS:STO) («Nexstim» or the «company«), a company within the targeted brain neuro-modulation that has developed and markets a ground-breaking system to navigate a non-invasive brain stimulation for therapeutic and diagnostic applications. The company reports the first six months to 30 June 2018 Thursday 16 August 2018 about 9 a.m. Finnish time.
A conference call targeted to the media, investors and analysts is arranged on Thursday 16 August 2018 at 16.00 Finnish time. Chairman of the board and managing director Martin Jamieson and cfo Mikko Karvinen presents the financial results and the profit after which participants are given the opportunity to ask questions.
Call into the conference call:
Finland: +358 (0) 800 914672
Sweden: +46 (0) 20 089 6377
Uk: +44 (0) 20 3003 2666
The united states: + 1 866 966 5335
International: +44 (0) 20 3003 2666
The call password: Nexstim
The financial report for the fiscal year ending december 31, 2018 will be published on or around 28 February 2019.
Martin Jamieson, chairman of the board and ceo
For more information go check on the company’s website at
Nexstim +44 77 1516 3942
Martin Jamieson, chairman of the board and ceo email@example.com
Sisu Partners Oy (Certified Adviser) +358 (0)10 231 4560
Citigate Dewe Rogerson +44 (0)207 2822949
David Dible/Shabnam Bashir firstname.lastname@example.org
About Nexstim Plc
Nexstim is a company in the targeted brain neuro-modulation that has developed and commercialize its world-leading technology in order to navigate non-invasive brain stimulation, called SmartFocusTM TMS (transcranial magnetstimulering) for therapeutic applications for the treatment of stroke, depression, and chronic pain through the corporate system to navigate hjärnterapi (NBT®).
Nexstim has launched its NBT®system in the united states for the treatment of major depressive disorder (MDD), after receiving approval from the FDA for marketing and sale for this indication. The NBT®system in Europe received CE marking for the treatment of stroke, major depression and chronic neuropathic pain.
The NBT®system is currently undergoing an additional Phase III trial (E-FIT) with 60 patients for use in stroke rehabilitation. Nexstim expects that the trial ends in mid-2018 and that the company can then apply for permission from the FDA. With the approval from the FDA would Nexstim able to begin marketing and selling the NBT®system for the treatment of stroke in the united states.
Nexstim commercializes also his NBS (Navigated Brain Stimulation) for diagnostic applications in the same technology platform. The NBS system is the only FDA-approved and CE-marked TMS-system for pre-operative mapping of the cortex for motor function and speech.
Nexstims shares are listed on Nasdaq First North Finland and Nasdaq First North Sweden. More information is available at www.nexstim.com.
Publishing of Nexstim Plc H1 2018
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Nexstim Oyj via Globenewswire